thereof; an optional co-solvent, and a gelling agent, wherein the co-solvent and gelling agent make up the balance of the composition.

[00019a] In a first aspect, there is provided a topical ophthalmic gel composition comprising 0.1%-10% w/w povidone-iodine; greater than 30% w/w DMSO; 0.05 % to 1.5% w/w steroid; and a gelling agent.

[00020] In an embodiment, disclosed herein is a pharmaceutical composition comprising povidone-iodine in a concentration between 0.01% and 10%, and a steroid selected from the group consisting of prednisolone acetate, loteprednol etabonate, difluprednate, and combinations thereof, wherein the steroid is at a concentration of between 0.05 and 1%. In an embodiment, the PVP-I is at a concentration of about 0.25%. In an embodiment, the steroid is at a concentration selected from the group consisting of about 1.0%, about 0.50%, about 0.25 %, 0.1%, about 0.05% and about 0.005%.

[00021] In an embodiment, an ophthalmic composition further comprises a composition that is free of a topical anesthetic because, advantageously, the subject composition is non-burning and non-irritating to the ocular surface and skin surrounding the eye.

[00022] In an embodiment, an ophthalmic composition is further free of an antimicrobial preservative.

[00023] In an embodiment, an ophthalmic composition optionally further comprises a co-solvent, surfactant, emulsifier or wetting agent. In an embodiment comprising a co-solvent, surfactant, emulsifier or wetting agent, the agent can be selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, Pluronic F-68, Pluronic F-84, Pluronic P-103, cyclodextrin, tyloxapol and the like, and combinations thereof. In an embodiment comprising co-solvent, surfactant, emulsifier or wetting agent, the agent can be provided at a concentration of about 0.01% to 2% by weight in said composition.

[00024] In an embodiment, an ophthalmic composition further comprises viscosity increasing, or gelling agent. In an embodiment, the viscosity increasing agent is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, or a cellulosic gelling agent such as methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethylcellulose, hydroxy propyl cellulose, or the like, and a combination thereof. In an embodiment, the viscosity increasing agent is at a concentration of about 0.01% to 5% by weight in said solution.

[00025] In an embodiment, an ophthalmic composition is in the form of a solution, suspension, emulsion, ointment, cream, gel, or a controlled-release/sustain-release vehicle.

CLAIMS

1. A topical ophthalmic gel composition comprising 0.1%-10% w/w povidone-iodine; greater than 30% w/w DMSO; 0.05 % to 1.5% w/w steroid; and a gelling agent.

2. The composition of claim 1, wherein the composition comprises a gelling agent selected from the group consisting of hydroxypropyl methylcellulose; hydroxyethyl cellulose; and hydroxymethyl cellulose.

3. The composition of claim 1, wherein the composition comprises a gelling agent selected from the group consisting of hydroxypropyl methylcellulose; hydroxyethyl cellulose; and hydroxymethyl cellulose and the gelling agent is present in a concentration between 0.5% to 3.0%, 1.0 to 2.5%, 1.25 to 2.25%, 1.5-2.0%, or 1.7 to 1.8%.

4. The composition of claim 1, wherein the composition comprises a steroid selected from the group consisting of prednisolone, difluprednate, and loteprednol or a salt or ester thereof.

5. The composition of claim 4 wherein the prednisolone is present at 1% w/w of the composition.

6. The composition of claim 4 wherein the prednisolone is present at 0.5% w/w of the composition.

7. The composition of claim 4 wherein the prednisolone acetate is present at 1% w/w of the composition.

8. The composition of claim 4 wherein the prednisolone acetate is present at 0.5% w/w of the composition.

9. The composition of claim 4 wherein the difluprednate is present at 0.05% w/w of the composition.

10. The composition of claim 4 wherein the loteprednol is present at 0.5% w/w of the composition.

11. The composition of claim 10 wherein the loteprednol is loteprednol etabonate.

12. The composition of claim 1 wherein the povidone-iodine is 0.25%-0.5% w/w of the composition.

13. Use of a composition of claim 1 in the manufacture of a medicament for treating an infectious or inflammatory eye condition.

14. The use of claim 13 wherein the eye condition is selected from bacterial or viral conjunctivitis; blepharitis; and corneal ulcer.